Journals / Nöropsikiyatri Arşivi / 2009 / Cilt: 46 - Sayı: 1

The efficacy and role of anticonvulsants as a treatment option in anxiety disorders

Anksiyete bozukluklarında antikonvülzanların etkinliği ve bir tedavi seçeneği olarak yeri

Pages
19–23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further research is needed to determine the efficacy of anticonvulsants as an alternative therapeutic option for the patients resistant to conventional treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Treatment options for anxiety disorders include pharmacotherapy and cognitive-behavioral therapy.
📊
Key Findings & Data:Selective serotonin reuptake inhibitors and serotonin noradrenalin reuptake inhibitors are the first-line pharmacological treatment approach for most of the anxiety disorders.
💡
Conclusion & Impact:Further research is needed to determine the efficacy of anticonvulsants as an alternative therapeutic option for the patients resistant to conventional treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tedavi sonucu · Antikonvülzanlar · Kaygı bozuklukları

Abstract

Treatment options for anxiety disorders include pharmacotherapy and cognitive-behavioral therapy. Selective serotonin reuptake inhibitors and serotonin noradrenalin reuptake inhibitors are the first-line pharmacological treatment approach for most of the anxiety disorders. The efficacy of anticonvulsants in anxiety disorders, including carbamazepine, lamotrigine, topiramate and gabapentin has been shown in some clinical studies. The strongest evidence has been provided for pregabalin and valproic acid in generalized anxiety disorder, pregabalin and gabapentin in social anxiety disorder, and lamotrigine in posttraumatic stress disorder. Further research is needed to determine the efficacy of anticonvulsants as an alternative therapeutic option for the patients resistant to conventional treatment.

Özet

Anksiyete bozukluklarında tedavi seçenekleri, ilaç tedavileri ve bilişsel-davranışçı tedavileri içerir. Çoğu anksiyete bozukluğu için ilaç tedavilerinin ilk basamağını, seçici serotonin gerialım inhibitörleri ve serotonin noradrenalin gerialım inhibitörleri oluşturmaktadır. Çeşitli çalışmalarda, karbamazepin, valproat, lamotrijin, topiramat, gabapentin ve pregabalini içeren antikonvülzanların anksiyete bozukluklarında etkili olduğu gösterilmiştir Anksiyete bozukluklarında antikonvülzanlar için en güçlü kanıtların; yaygın anksiyete bozukluğu için pregabalin ve valproik asit, sosyal anksiyete bozukluğu için pregabalin ve gabapentin, travma sonrası stres bozukluğu için lamotrijin ile sağlandığı görülmektedir. Antikonvülzanların, geleneksel tedavilere dirençli hastalarda alternatif bir tedavi seçeneği olarak etkinliğini belirlemek üzere daha ileri çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TÜKEL, R. (2009). The efficacy and role of anticonvulsants as a treatment option in anxiety disorders. Nöropsikiyatri Arşivi, Cilt: 46 - Sayı: 1, 19–23. https://ajindex.com/articles/292780

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
  2. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51(Suppl. 2):9S-91S
  3. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263-72
  4. Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-96
  5. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9: 248-312
  6. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacology & Therapeutics 2007; 113: 165-83
  7. Kiura Y, Hanaya R, Serikawa T et al. Involvement of Ca(2+) channels in abnormal excitability of hippocampal CA3 pyramidal cells in noda epileptic rats. J Pharmacol Sci 2003; 91: 137-44
  8. Turner TJ. Calcium channels coupled to glutamate release. Prog Brain Res 1998; 116: 3-14
  9. White H S, Brown SD, Woofhead et al. Topiramate modulates GABA evoked currents in murine cortical neurons by a non-benzodiazepine mechnism. Epilepsia 2000; 41: 17-20
  10. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998; 44: 1264-76
  11. Stutzmann GE, LeDoux JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci 1999; 19: RC8
  12. Stahl SM. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry 2002; 63: 854-5
  13. Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 2003; 64: 1421-5
  14. Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. 2nd ed. New York, NY: Cambridge University Press, 2002
  15. Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry 2004; 65: 4